Agonists directed against the α and γ isoforms of the peroxisome proliferator-activated
receptors (PPARs) have become important for the respective treatment of …

The Pharmacogenomics Journal (2006) 6, 360–374. doi: 10.1038/sj. tpj. 6500384;
published online 21 March 2006 β-hydroxy-β-methylglutaryl Coenzyme A (HMG-CoA) …

Background—Statins are effective at lowering low-density lipoprotein cholesterol and
reducing risk of cardiovascular disease, but variability in response is not well understood. To …

Objectives: We sought to determine the effects of PCSK9 variants on plasma low-density
lipoprotein cholesterol (LDL-C) levels, severity of coronary atherosclerosis, and response to …

The prevention of cardiovascular disease is critically dependent on lipid-lowering therapy,
including 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors …

Despite the benefit of statin therapy in the prevention of coronary heart disease, a
considerable inter-individual variation exists in its response. It is well recognized that genetic …

Background The identification of genetic variants related to blood lipid levels within a large,
population-based and nationally representative study might lead to a better understanding …

Genetic components may play an important role in the regulation of nutrient and energy
metabolism. In the presence of specific genetic variants, metabolic dysregulation may occur …

Background Fluvastatin is thought to be the least potent statin on the market, however, the
dose‐related magnitude of effect of fluvastatin on blood lipids is not known. Objectives …

Interindividual variability in response to 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase
inhibitors, or statins, with regard to both efficacy and safety is an obvious target for …